

SecureEMR version 5.0 Real World Testing Plan CY2025

Developer Name:	Inmediata Health Group
Product Name:	SecureEMR
Version Number:	5.0
CHPL ID:	15.07.07.2769.SE01.01.00.1.210408
RWT Page URL:	https://portal.inmediata.com/emr/#rwt



Overall Testing Plan

Justification for Real World Testing Approach

Inmediata Health Group will be conducting a Real World Testing using SecureEMR 5.0 to measure the end-user engagement and effectiveness of the E-Prescribing [criteria 170.315(b)(3)] and Electronic Health Information Export [criteria 170.315(b)(10)] modules of our EHR.

E-Prescribing is a very important module to our end-users and their patients since it simplifies the process for fulfilling and renewing prescriptions.

Electronic Health Information Export allows providers to extract single or multiple patients' health records to share with patients or external organizations.

Standards Updates (SVAP and USCDI)

NCPDP Standard V2017071

Care Setting

Ambulatory

Overall Expected Outcome

- Real World Testing will allow us to learn more about the engagement and effectiveness of our users in important modules of the application using statistical reports from real users in our production environment.

Measures Used

Measure #1

- **Certification Criteria:**

170.315(b)(3) E-Prescribing

- **Justification**

E-Prescribing is a very important module to our end-users and their patients since it simplifies the process for fulfilling and renewing prescriptions.

- **Test Methodology**

Our approach is to use deidentified analytics reports to measure the use of electronic prescriptions transactions (new prescriptions and refill requests) from our providers.

We will also measure the error rate for the transactions submitted to our e-prescriptions clearinghouse to demonstrate our compliance with NCPDP Standard V2017071.

- **Relied upon software**

Our application relies on **Surescripts** as our e-prescription hub and **First Data Bank MedKnowledge** as our medications database to meet criteria 170.315(b)(3)

E-Prescribing. We will analyze the responses from Surescripts to measure the error rate for our providers using electronic prescriptions. At this time, the real-world testing will not be considering specific medications from the FDB data source.

- **Expected Outcome**

1. Real World Testing will show a high rate of usage in the prescription module with our providers in comparison to those users that are not using this module
2. Real World Testing will show a higher rate of electronic prescriptions in comparison to those prescriptions sent by fax to the pharmacies
3. Real World Testing will show a low rate of errors from our prescription hub

Measure #2

- **Certification Criteria:**

170.315(b)(10) Electronic Health Information Export

- **Justification**

Electronic Health Information Export is a very important module to our end-users and their patients since it allows the export of health record based on a single patient or multiple patients at the same time which can be used for transition of care or sharing health data with external organizations.

- **Test Methodology**

Our approach is to use deidentified analytics reports to measure the usage history and statistics of electronic health record export from our providers.

- **Relied upon software**

None

- **Expected Outcome**

1. Real World Testing will show frequency of use of the data export module by our users during the reporting period with a distribution by single patient or full practice export
2. Real World Testing will show the average processing time for producing the exported data for a user

Schedule of Key Milestones CY2024

Key Milestone	Date
Develop reports	1/20/2025
Execute preliminary reports	4/14/2025
Analyze preliminary reports	6/16/2025
Execute and analyze final reports	1/5/2026
Create final RWT Document	1/12/2026
Submit final RWT Document to Drummond Group	2/2/2026

This Real World Testing plan is complete with all required elements, including measures that address all certification criteria and care settings. All information in this plan is up to date and fully addresses the health IT developer's Real World Testing requirements.

Authorized Representative Name: Camilo Torres

Authorized Representative Email: ctorres@inmediata.com

Authorized Representative Phone: 787-783-3233

Authorized Representative Signature: *Camilo Torres*

Date: 11/6/2024